Ravi Shridhar, MD
Disclosures: Speakers Bureau-Boston Scientific Corporation|Speakers Bureau-AstraZeneca - 08/26/2022
OMB No. 0925-0046, Biographical Sketch Format Page

 

OMB No. 0925-0001 and 0925-0002 (Rev. 03/2020 Approved Through 02/28/2023)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person.  DO NOT EXCEED FIVE PAGES.

NAME: Ravi Shridhar MD, PhD

eRA COMMONS USER NAME (credential, e.g., agency login): RaviShridhar

POSITION TITLE: Vice-Chair of Radiation Oncology

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

 

Completion Date

MM/YYYY

 

FIELD OF STUDY

 

Wayne State University School of Medicine, Detroit, MI

Wayne State University School of Medicine, Detroit, MI

Wayne State University School of Medicine, Detroit, MI

William Beaumont Hospital, Royal Oak, MI

Detroit Receiving Hospital/Karmanos Cancer

Institute, Wayne State University, Detroit, MI

BA

MD

PhD

Intern

Resident

08/1992–12/1995

08/1996-05/2004

09/2004-10/2001

07/2004-06/2005

07/2005-06/2009

Chemistry

MD

Pharmacology

Internal Medicine

Radiation Oncology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1. Personal Statement

I am a board-certified radiation oncologist who specializes in the treatment of gastrointestinal malignancies. I am involved with the treatment of esophageal, gastric, small intestinal, colorectal, anal, pancreaticobiliary and hepatic malignancies (primary and secondary). I oversee radiation oncology for the treatment of GI cancers at Advent Health. I have been instrumental in leading and overseeing treatment programs of Y90 for liver cancer and metastases and Lutathera for treatment of neuroendocrine carcinomas. I am the radiation oncology representative for the rectal cancer program as part of accreditation by the American College of Surgeons and Commision on Cancer.

 

 

B.              Positions and Honors
2009-2014                             Assistant Member, Moffitt Cancer Center & Research Institute, Tampa, FL

2009-2014                             Assistant Professor, Dept of Oncologic Sciences, College of Medicine, University of South

Florida, Tampa, FL

2014                                                         Associate Member, Moffitt Cancer Center & Research Institute, Tampa, FL

2014              Associate Professor, Dept of Oncologic Sciences, University of South Florida College of Medicine, Tampa, FL

2014-present              Associate Investigator; Florida Hospital Cancer Institute; Florida Hospital Orlando, Orlando, FL

Other Experience and Professional Memberships:

2009-present:                             American Society for Radiation Oncology (ASTRO)

2013-present:              Coordinator, E-Contouring Esophageal Cancer Committee, American Society for Radiation Oncology (ASTRO)

2013-2014:              Junior Investigator, National Cancer Institute, Esophagogastric Task Force of the GI     Steering Committee (GISC)

Honors:

1992              Presidential Merit Scholarship; Wayne State University, Detroit, MI

1993              Howard Hughes Undergraduate Summer Research Fellowship; Wayne State University, Detroit, MI

2002              1st Place Oral Presentation; 10th Annual Medical Student Research Symposium; Wayne State Univ., Detroit, MI

2002              Hershel and Lois Sandberg Award for Excellence in Medical Research; 10th Annual Medical Student

Research Symposium; Wayne State University; Detroit, MI

2003              UTMB Cancer Center Award for Best Oncologic Research; 44th Annual National Student Research Forum; University of Texas Medical Branch, Galveston, TX

2003              AMA Foundation Award for Best Clinical Research; 44th Annual National Student Research Forum;

University of Texas Medical Branch, Galveston, TX

2003              Sigma Xi Award for Best Overall Research; 44th Annual National Student Research Forum; University of Texas Medical Branch, Galveston, TX

2009              Roentgen Resident/Fellow Research Award, Dept of Radiation Oncology, Wayne State University, Detroit, MI

2009              Travel Grant, ASTRO, Chicago IL

2012              Travel Grant, SWOG, Chicago, IL

2013    SWOG Young Investigator Training Course, funded by SWOG/The Hope Foundation, Seattle, WA

 

 

  1. Contributions to Science

  2. Researchers at Moffitt derived a 10 gene signature that predicts for radiosensitivity of radiated tissues.  It has been extensively validated in breast, lung, GBM, rectal, esophageal, prostate, and head-neck cancers. In a comprehensive evaluation of 13,600 patients with solid tumors, a spectrum of radiosensitivity and radioresistance was observed where diseases sites like brain, pancreas, sarcoma, melanoma, and thyroid were ranked as radioresistant, while HPV-related cancers like cervical and head and neck cancers were radiosensitive. This had great potential to identify patients who will benefit from radiation and avoid treating radioresistant patients and spare them toxicity of treatment.

 

I was involved as a Co-Investigator in prospective trials validating the biomarker in esophageal and rectal cancers where I was responsible for the majority of enrollment and accrual. This trial was supported with a R21 grant. I was awarded a grant from the Florida Department of Health to utilize the biomarker to predict outcome for borderline resectable pancreatic cancer treated with chemoradiation. I have also presented the biomarker at SWOG on several occasions and was awarded the Young Investigator Training Course where my proposal was to incorporate the radiation biomarker in predicting response to preoperative chemoradiation for gastric cancer.  It was suggested to test SWOG samples prior to initiating a trial. I submitted a translational medicine proposal to access gastric cancer samples from the intergroup 0116 trial where resected patients were randomized to observation versus chemoradiation which was approved.  I was involved with an analysis of metastatic colorectal cancer where we show that lung metastases were more radiosensitive compared to liver metastases and confirmed with recurrence outcomes in patients with radiation treated liver or lung metastases. We also applied the RSI signature to resected pancreatic cancer who received adjuvant chemoradiation and found it to be prognostic.

 

  1. Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, Shridhar R, Torres-Roca JF. Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. International Journal of Radiation Oncology, Biology, Physics. 2015. July;92(4):837-842. PMID: 25838188; PMCID: PMC4481172.

 

  1. Strom T, Hoffe SE, Fulp W, Frakes J, Coppola D, Springett GM, Malafa MP, Harris CL, Eschrich SA, Torres-Roca JF, Shridhar R. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology. 2015. Oct;117(1):159-164. PMID: 23265848.

 

Complete List of Published Work in MyBibliography:

 http://www.ncbi.nlm.nih.gov/sites/myncbi/1Fq8c12q98556/bibliography/48216632/public/?sort=date&direction=ascending.

 

D.              Additional Information: Research Support and/or Scholastic Performance